Balanced news tone
News Sentiment
SANA sentiment intelligence
Sana Biotechnology Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Weighted score
53
Balanced news tone
62 relevant articles
Price is moving more forcefully than the current news tone suggests.
79/100 classification confidence.
directly relevant articles
high-authority source matches
-4.0% over one week, +43.7% over four weeks, trend inactive, and near fair-value range.
Sana Biotechnology (SANA) Edges Lower Amid Biotech Sector Volatility; Key Support Levels in Focus - Tick Index
Market Reaction
Price moving ahead of tone
Price is moving more forcefully than the current news tone suggests.
Primary event
Market update
79/100 classification
One-week reaction
-4.0%
Price reacting lower
Trend fit
Trend inactive
43.7% over four weeks
Fair value
-11.8%
Near fair-value range
Sentiment Mix
Positive, neutral, negative
Positive
17
Neutral
34
Negative
11
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
Above 50
Neutral zone
Below 50
News Tape
Relevant headlines
dars.gov.et
Direct company coverage
Sana Biotechnology (SANA) Edges Lower Amid Biotech Sector Volatility; Key Support Levels in Focus - Tick Index
- Tone
- Negative 34/100
- Event
- Market update
- Published
- 15 Jul 2026 16:40
- Source
- dars.gov.et
StockStory
Direct company coverage
Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 15 Jul 2026 07:00
- Source
- StockStory
GlobeNewswire
Direct company coverage
Sana Biotechnology Announces Follow-On Publication in The New England Journal of Medicine (NEJM) Highlighting Groundbreaking Long-Term Data and Durability of Hypoimmune-Modified Islet Cell Transplantation Without Immunosuppression in Type 1 Diabetes
Sana Biotechnology announced a follow-on publication in The New England Journal of Medicine (NEJM) detailing 14-month follow-up data from an investigator-sponsored study of UP421, a hypoimmune-modified islet cell therapy for Type 1 Diabetes. The data reinforces that HIP-modified
- Tone
- Positive 92/100
- Event
- Market update
- Published
- 13 Jul 2026 22:11
- Source
- GlobeNewswire
Market source
Direct company coverage
Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 13 Jul 2026 12:30
- Source
- Market source
Quartr
Direct company coverage
Sana Biotechnology (SANA) Morgan Stanley 23rd Annual Global Healthcare Conference summary
Sana Biotechnology (SANA) presented at the Morgan Stanley 23rd Annual Global Healthcare Conference, outlining its strategic vision to revolutionize medicine through gene and cell-based therapies, specifically targeting allogeneic transplant rejection and precise genetic repair. T
- Tone
- Positive 73/100
- Event
- Market update
- Published
- 08 Jul 2026 21:10
- Source
- Quartr
Quartr
Direct company coverage
Sana Biotechnology (SANA) 43rd Annual J.P. Morgan Healthcare Conference 2025 summary
Sana Biotechnology presented key scientific advances and clinical data at the 43rd Annual J.P. Morgan Healthcare Conference 2025, highlighting the first successful transplant of gene-edited allogeneic islet cells in a type 1 diabetes patient without immunosuppression. The company
- Tone
- Positive 72/100
- Event
- Market update
- Published
- 08 Jul 2026 21:10
- Source
- Quartr
Simply Wall Street
Direct company coverage
Sana Biotechnology (SANA) Is Up 18.1% After Removal From Key Russell Value Indexes - What's Changed
Sana Biotechnology (SANA) was recently removed from several Russell value benchmarks, including the Russell 3000 Value and Russell 2000 Value indexes. This removal impacts how index funds and institutional investors view the stock, but it doesn't change the company's scientific o
- Tone
- Negative 38/100
- Event
- Market update
- Published
- 08 Jul 2026 20:07
- Source
- Simply Wall Street
Longevity.Technology
Direct company coverage
Sana Biotech heads to EASD with diabetes cell therapy update
Sana Biotechnology will present clinical findings from its first-in-human study of UP421 at the European Association for the Study of Diabetes (EASD) Annual Meeting 2026. This experimental cell therapy is designed to make transplanted insulin-producing cells "hidden" from the imm
- Tone
- Positive 82/100
- Event
- Market update
- Published
- 08 Jul 2026 14:39
- Source
- Longevity.Technology
Quartr
Direct company coverage
Sana Biotechnology (SANA) Bank of America Global Healthcare Conference 2026 Summary
Sana Biotechnology (SANA) delivered a summary at the Bank of America Global Healthcare Conference 2026, highlighting its dual strategic focus on engineering cells both ex vivo (for cell replacement in Type 1 diabetes) and in vivo (for cell repair/signaling change in CAR-T therapy
- Tone
- Positive 75/100
- Event
- Market update
- Published
- 08 Jul 2026 08:41
- Source
- Quartr
Moomoo
Direct company coverage
Sana Biotechnology | 4: Statement of changes in beneficial ownership of securities-Director Bishop Hans Edgar
This document from Sana Biotechnology details a Statement of changes in beneficial ownership of securities for Director Bishop Hans Edgar. The filing is a routine disclosure of insider transactions as required by the SEC.
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 08 Jul 2026 04:11
- Source
- Moomoo
Investing.com Nigeria
Direct company coverage
Form 4 Sana Biotechnology Inc For: 7 July By Investing.com
This article reports on a Form 4 filing for Sana Biotechnology Inc. on July 7, 2026, as published by Investing.com. It is a brief announcement indicating an insider transaction or change in beneficial ownership for the company. The article contains minimal detail beyond the initi
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 07 Jul 2026 20:39
- Source
- Investing.com Nigeria
Stock Titan
Direct company coverage
Sana Biotechnology (SANA) director Hans Bishop receives 6,297 vested RSU shares
Sana Biotechnology director Hans Edgar Bishop received 6,297 fully vested restricted stock units (RSUs) as a compensation-related grant, increasing his direct holdings to 5,854,800 shares. The Form 4 filing indicates this was a stock grant at a price of $0.00 per share, not an op
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 07 Jul 2026 20:11
- Source
- Stock Titan
Sahm
Direct company coverage
Will Removal From Russell Value Benchmarks Change Sana Biotechnology's (SANA) Institutional Investor Narrative?
Sana Biotechnology (SANA) was recently removed from several Russell value-oriented benchmarks, including the Russell 2000, which could impact its institutional investor base and liquidity. Despite potential short-term pressure, the article suggests that the company's clinical mil
- Tone
- Negative 36/100
- Event
- Balance sheet
- Published
- 03 Jul 2026 07:39
- Source
- Sahm
The National Law Review
Direct company coverage
SANA LAWSUIT ALERT: Levi & Korsinsky Notifies Sana Biotechnology, Inc. Investors - Lead Plaintiff Deadline May 20, 2025
Levi & Korsinsky, LLP has filed a class action securities lawsuit against Sana Biotechnology, Inc. (NASDAQ:SANA) for alleged securities fraud between March 17, 2023, and November 4, 2024. The lawsuit claims Sana made false statements and concealed risks regarding its financial ca
- Tone
- Negative 30/100
- Event
- Regulatory and legal
- Published
- 02 Jul 2026 18:41
- Source
- The National Law Review
Market source
Direct company coverage
Sana Biotechnology Announces Symposium Presentation at the European Association for the Study of Diabetes (EASD) Annual Meeting 2026
Sana Biotechnology will present clinical data at the European Association for the Study of Diabetes (EASD) Annual Meeting 2026. The presentation will highlight results from a first-in-human study of UP421, an allogeneic primary islet cell therapy engineered with Sana's hypoimmune
- Tone
- Positive 71/100
- Event
- Earnings
- Published
- 02 Jul 2026 07:41
- Source
- Market source
Stock Titan
Direct company coverage
Sana to show first-in-human islet transplant data without immunosuppression
Sana Biotechnology (NASDAQ: SANA) is set to present clinical data on UP421, an allogeneic primary islet cell therapy utilizing its hypoimmune platform, at the European Association for the Study of Diabetes (EASD) Annual Meeting 2026. This first-in-human transplant data for type 1
- Tone
- Positive 67/100
- Event
- Market update
- Published
- 01 Jul 2026 12:40
- Source
- Stock Titan
GlobeNewswire
Direct company coverage
Sana Biotechnology Announces Symposium Presentation at the
Sana Biotechnology, Inc. (NASDAQ: SANA) announced a symposium presentation at the European Association for the Study of Diabetes (EASD) Annual Meeting 2026. The presentation will highlight clinical data from a first-in-human study of UP421, an allogeneic primary islet cell therap
- Tone
- Positive 74/100
- Event
- Market update
- Published
- 01 Jul 2026 12:40
- Source
- GlobeNewswire
Investing.com
Direct company coverage
Citizens reiterates Sana Biotechnology stock rating on IND filing
Citizens has reiterated a Market Outperform rating and an $8.00 price target for Sana Biotechnology (NASDAQ:SANA) following the company's plans to file an Investigational New Drug application for SG293, their first fusogen-based in vivo CAR-T program. Although the stock currently
- Tone
- Positive 72/100
- Event
- Analyst action
- Published
- 01 Jul 2026 09:40
- Source
- Investing.com
www.marketscreener.com
Direct company coverage
Sana Biotechnology, Inc.(NasdaqGS: SANA) dropped from Russell 3000 Value Benchmark
Sana Biotechnology, Inc. (NasdaqGS: SANA) has been removed from the Russell 3000 Value Benchmark. This news follows several other index removals for the company, including the Russell Small Cap Comp Value Benchmark, Russell 2500 Value Benchmark, and Russell 2000 Value Benchmark.
- Tone
- Negative 30/100
- Event
- Market update
- Published
- 29 Jun 2026 17:10
- Source
- www.marketscreener.com
marketscreener.com
Direct company coverage
Sana Biotechnology, Inc.(NasdaqGS: SANA) dropped from Russell 2500 Value Benchmark
Sana Biotechnology, Inc. (NasdaqGS: SANA) has been removed from the Russell 2500 Value Benchmark. This news comes amidst several other recent announcements regarding the company's removal from various Russell indices and presentations at healthcare conferences, as well as an equi
- Tone
- Negative 29/100
- Event
- Market update
- Published
- 29 Jun 2026 05:10
- Source
- marketscreener.com
The National Law Review
Direct company coverage
Join Class Action to Recover Losses from Sana Biotechnology, Inc. (SANA) - Contact Levi & Korsinsky Before May 20, 2025
Levi & Korsinsky, LLP has filed a class action securities lawsuit against Sana Biotechnology, Inc. (NASDAQ: SANA) seeking to recover losses for shareholders who purchased shares between March 17, 2023, and November 4, 2024. The lawsuit alleges that Sana Biotechnology made false s
- Tone
- Negative 29/100
- Event
- Regulatory and legal
- Published
- 28 Jun 2026 05:10
- Source
- The National Law Review
The National Law Review
Direct company coverage
Lost Money on Sana Biotechnology, Inc. (SANA)? Contact Levi & Korsinsky to Join Class Action Before May 20, 2025
Levi & Korsinsky LLP has filed a class action securities lawsuit against Sana Biotechnology, Inc. (NASDAQ: SANA) for alleged securities fraud between March 17, 2023, and November 4, 2024. The lawsuit claims Sana overstated its financial capacity and the prospects of certain produ
- Tone
- Negative 15/100
- Event
- Regulatory and legal
- Published
- 27 Jun 2026 15:10
- Source
- The National Law Review
TradingView
Direct company coverage
Price to earnings forward of Sana Biotechnology, Inc. – NASDAQ:SANA
This page from TradingView displays financial information for Sana Biotechnology, Inc. (NASDAQ: SANA), specifically focusing on its price-to-earnings forward metric. The content indicates that the company's market data is closed with no trades. The article is a financial data pag
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 27 Jun 2026 04:10
- Source
- TradingView
TradingView
Direct company coverage
Enterprise value to EBIT forward of Sana Biotechnology, Inc. – NASDAQ:SANA
This article provides the enterprise value to EBIT forward for Sana Biotechnology, Inc. (NASDAQ: SANA). It presents financial data via TradingView, indicating no current trades and a closed market for the stock. The content primarily focuses on the financial metric for SANA.
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 27 Jun 2026 02:10
- Source
- TradingView
TradingView
Direct company coverage
Sana Biotechnology, Inc. Actuals & Estimates (NASDAQ:SANA)
This article provides an overview of Sana Biotechnology, Inc. (NASDAQ:SANA)'s financial actuals and estimates. It covers the current stock price, historical highs and lows, market capitalization, earnings reports, revenue, net income, and analyst forecasts for future price target
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 25 Jun 2026 19:10
- Source
- TradingView
TradingView
Direct company coverage
SANA Forecast — Price Target — Prediction for 2027
The article provides a forecast for Sana Biotechnology, Inc. (SANA) stock, including current price, analyst ratings, and historical performance. Analysts project a max estimate of $16.00 and a min estimate of $7.00 for SANA, with a current price of $3.26. The company's financials
- Tone
- Neutral 50/100
- Event
- Analyst action
- Published
- 25 Jun 2026 14:41
- Source
- TradingView
TradingKey
Direct company coverage
Puma Biotechnology Inc (PBYI) Earnings Forecast: Future EPS & Revenue Growth Estimates
- Tone
- Positive 66/100
- Event
- Earnings
- Published
- 18 Jun 2026 05:53
- Source
- TradingKey
TradingKey
Direct company coverage
Sana Biotechnology Inc (SANA) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides an overview of Sana Biotechnology Inc's (SANA) dividends and stock splits. It indicates that the company has not distributed any dividends over the past five years and has no recorded stock splits. The page also displays current stock prices and market capit
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 17 Jun 2026 09:11
- Source
- TradingKey
TradingKey
Direct company coverage
Sana Biotechnology Inc (SANA) Earnings Forecast: Future EPS & Revenue Growth Estimates
This article provides an earnings forecast for Sana Biotechnology Inc (SANA), including analyst ratings, price targets, and EPS estimates. Based on 9 analysts, the stock has a "Buy" rating with a target price of $7.00, representing a significant upside. The report also highlights
- Tone
- Positive 66/100
- Event
- Earnings
- Published
- 17 Jun 2026 03:11
- Source
- TradingKey
TradingView
Direct company coverage
Sana Biotechnology, Inc. Stock 12‑Month Price Target Cut to $9.14, Implies 230% Upside
Sana Biotechnology, Inc.'s average 12-month price target has been lowered from $9.50 to $9.14 by 7 analysts, with individual forecasts ranging from $7 to $16 per share. This updated target suggests a potential upside of approximately 230% from its Jun. 11 closing price. Despite t
- Tone
- Positive 74/100
- Event
- Analyst action
- Published
- 12 Jun 2026 04:09
- Source
- TradingView